Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo – 16 January 2016 – Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved.

Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo – 16 January 2016 – Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved.

A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation

Satoru Todo, Kenichiro Yamashita, Ryoichi Goto, Masaaki Zaitsu, Akihisa Nagatsu, Tetsu Oura, Masaaki Watanabe, Takeshi Aoyagi, Tomomi Suzuki, Tsuyoshi Shimamura, Toshiya Kamiyama, Norihiro Sato, Junichi Sugita, Kanako Hatanaka, Hisashi Bashuda, Sonoko Habu, Anthony J. Demetris, Ko Okumura – 16 January 2016 – Potent immunosuppressive drugs have significantly improved early patient survival after liver transplantation (LT). However, long‐term results remain unsatisfactory because of adverse events that are largely associated with lifelong immunosuppression.

Subscribe to